Diabetic cardiomyopathy

Lee, Matthew M Y; McMurray, John J.V.; Lorenzo-Almorós, Ana; Kristensen, Søren Lund; Sattar, Naveed; Jhund, Pardeep S.; Petrie, Mark C.

doi:10.1136/heartjnl-2016-310342

Cited by 83 publications

(80 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, DCM progression leads to reduced myocardial contractility and relaxation, ultimately leading to heart failure with reduced ejection fraction (HFrEF) [18]. The mechanisms underlying the development of DCM are summarized Figure 1 (adapted from [19]).…”

Section: Definition and Characteristics Of Dcmmentioning

confidence: 99%

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Seo

Jang

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is associated with cardiovascular, ophthalmic, and renal comorbidities. Among these, diabetic cardiomyopathy (DCM) causes the most severe symptoms and is considered to be a major health problem worldwide. Exercise is widely known as an effective strategy for the prevention and treatment of many chronic diseases. Importantly, the onset of complications arising due to diabetes can be delayed or even prevented by exercise. Regular exercise is reported to have positive effects on diabetes mellitus and the development of DCM. The protective effects of exercise include prevention of cardiac apoptosis, fibrosis, oxidative stress, and microvascular diseases, as well as improvement in cardiac mitochondrial function and calcium regulation. This review summarizes the recent scientific findings to describe the potential mechanisms by which exercise may prevent DCM and heart failure.

show abstract

Section: Definition and Characteristics Of Dcmmentioning

confidence: 99%

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Seo

Jang

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The reduction in the rates of hospitalization for heart failure may well have its foundation upon the diuretic and natriuretic effects of these drugs with concomitant benefits upon ventricular pre-and afterload. However, the evolution of the diabetic cardiomyopathy (DMCM) through left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) and concluding with a dilated cardiomyopathy and heart failure with reduced ejection fraction (HFrEF, Figure 2) is a complex pathophysiological process, 11,12 one in which SGLT2is may interact.…”

Section: Sglt2 Inhibitorsmentioning

confidence: 99%

“…Indeed, SGLT2is appear to have a positive impact upon left ventricular mass in the earlier phases of DMCM and improved ventricular performance (reviewed in ref 13). The ventricular remodeling and progression from HFpEF to HFrEF appear to be characterized by ischemic heart disease and ischemia/reperfusion injury, 11,12 and this too represents a target for SGLT2is. EMPA-REG, CANVAS, and DECLARE were not studies designed to look at myocardial infarction (the number of fatal myocardial infarcts were very low, even within the high-risk population recruited into EMPA-REG).…”

Section: Sglt2 Inhibitorsmentioning

confidence: 99%

Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy

2019

Heart Metab

View full text Add to dashboard Cite

Recent cardiovascular outcome trials (CVOTs) have transformed the landscape for the management of type 2 diabetes mellitus. In a remarkably short period of time, national and international guidelines have been overhauled to reflect the remarkable cardiovascular benefits of sodium/glucose linked transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor analogues (GLP-1RA) in mitigating cardiovascular risk. Both SGLT2is and GLP-1RAs remain second-line to metformin, reflecting the historical importance of this biguanide antihyperglycemic. In this review, these three very different antihyperglycemics are discussed in the light of CVOT data and of the preclinical data revealing remarkable pleiotropic signaling effects of these drugs. A model of diabetic cardiomyopathy is discussed, and the points of contact that these therapeutic interventions have upon this model may of help in understanding how each can be best targeted in this complex pathophysiological disease process.

show abstract

“…Recently Lee et al proposed a pragmatic definition of diabetic cardiomyopathy which will be used here -"cardiac abnormalities not wholly explained by other cardiovascular or non-cardiovascular causes and likely to be due to diabetes." 5 The factors which underpin myocardial dysfunction in diabetes are described in detail elsewhere in this issue of Heart & Metabolism. However, diagnosis is founded on the basis that diabetic cardiomyopathy comprises structural, functional, and molecular alterations which can be assessed using appropriate imaging or biomarkers.…”

Section: What Is Diabetic Cardiomyopathy?mentioning

confidence: 99%

Diagnosing diabetic cardiomyopathy

2019

Heart Metab

View full text Add to dashboard Cite

Diabetic cardiomyopathy reflects the presence of structural or functional abnormalities of the myocardium in an individual with diabetes which are not fully explained by other factors known to cause myocardial dysfunction. Diabetes promotes a range of molecular and cellular changes leading to left ventricular concentric hypertrophy, fibrosis, abnormal perfusion, lipid deposition, altered metabolism, diastolic dysfunction, and later progression to systolic dysfunction. Diagnosis of diabetic cardiomyopathy requires identification of such pathological features whilst at the same time excluding other causes of left ventricular dysfunction. In this article, avail- able modalities which can contribute to a diagnosis of diabetic cardiomyopathy are discussed. In most cases a diagnosis of diabetic cardiomyopathy can be reached by echocardiography or cardiac magnetic resonance imaging to detect structural and functional myocardial changes, with computed tomography coronary angiography being employed to exclude obstructive coronary artery disease which could account for left ventricular dysfunction.

show abstract

Diabetic cardiomyopathy

Cited by 83 publications

References 94 publications

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms

Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy

Diagnosing diabetic cardiomyopathy

Contact Info

Product

Resources

About